BUDGET IMPACT ANALYSIS OF TRASTUZUMAB EMTANSINE FOR RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN ARGENTINA

被引：0
|
作者：
Penayo, N. [1 ]
Peredo, S. [2 ]
Olivera, M. S. [1 ]
Weissberg, A. [1 ]
Tellechea, F. [1 ]
Saenz, V [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Tigre, Argentina
[2] F Hoffmann Roche Ltd, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN62
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [1] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [2] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [3] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [4] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Katherine A. Lyseng-Williamson
    Drugs, 2020, 80 : 1723 - 1730
  • [5] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [6] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (16) : 1723 - 1730
  • [7] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [8] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [9] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Loibl, Sibylle
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Geyer, Charles E.
    Untch, Michael
    Thery, Jean-Christophe
    Schwaner, Ingo
    Limentani, Steven
    Loman, Niklas
    Lubbe, Kristina
    Chang, Jenny C.
    Hatschek, Thomas
    Tesarowski, David
    Song, Chunyan
    de Haas, Sanne Lysbet
    Boulet, Thomas
    Lambertini, Chiara
    Wolmark, Norman
    NPJ BREAST CANCER, 2022, 8 (01)
  • [10] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Sibylle Loibl
    Chiun-Sheng Huang
    Max S. Mano
    Eleftherios P. Mamounas
    Charles E. Geyer
    Michael Untch
    Jean-Christophe Thery
    Ingo Schwaner
    Steven Limentani
    Niklas Loman
    Kristina Lübbe
    Jenny C. Chang
    Thomas Hatschek
    David Tesarowski
    Chunyan Song
    Sanne Lysbet de Haas
    Thomas Boulet
    Chiara Lambertini
    Norman Wolmark
    npj Breast Cancer, 8
12345